The Firm is representing CSL Behring in connection with the formation of the CoVIg-19 Plasma Alliance, an unprecedented partnership of the world’s leading plasma companies, spanning plasma collection, development, production and distribution. CSL Behring and Takeda are the founders of the Alliance. In addition to CSL Behring, the Plasma Alliance’s members include Biotest, LFB, Octapharma, Takeda and several other companies.
The Plasma Alliance is seeking to develop CoVIg-19, a potential plasma-derived therapy for treating COVID-19. The Plasma Alliance will work toward developing the unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals at the onset of clinical progression, but prior to development of serious complications, and to support national governments in their efforts to fight the current pandemic.
The Simpson Thacher team includes Mark Pflug, Eric Swedenberg and Yui Hirohashi (M&A); Sara Razi, John Goheen, Preston Miller and Nicholas Ingros (Antitrust); Lori Lesser (Intellectual Property); and Vanessa Burrows (Healthcare).